1362 related articles for article (PubMed ID: 25483639)
1. Antigen-specific vaccines for cancer treatment.
Tagliamonte M; Petrizzo A; Tornesello ML; Buonaguro FM; Buonaguro L
Hum Vaccin Immunother; 2014; 10(11):3332-46. PubMed ID: 25483639
[TBL] [Abstract][Full Text] [Related]
2. DNA vaccine for cancer immunotherapy.
Yang B; Jeang J; Yang A; Wu TC; Hung CF
Hum Vaccin Immunother; 2014; 10(11):3153-64. PubMed ID: 25625927
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic gene modified cell based cancer vaccines.
Kozłowska A; Mackiewicz J; Mackiewicz A
Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
[TBL] [Abstract][Full Text] [Related]
4. Tumor cell lysates as immunogenic sources for cancer vaccine design.
González FE; Gleisner A; Falcón-Beas F; Osorio F; López MN; Salazar-Onfray F
Hum Vaccin Immunother; 2014; 10(11):3261-9. PubMed ID: 25625929
[TBL] [Abstract][Full Text] [Related]
5. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
Seledtsov VI; Goncharov AG; Seledtsova GV
Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
[TBL] [Abstract][Full Text] [Related]
6. DNA vaccines, electroporation and their applications in cancer treatment.
Lee SH; Danishmalik SN; Sin JI
Hum Vaccin Immunother; 2015; 11(8):1889-900. PubMed ID: 25984993
[TBL] [Abstract][Full Text] [Related]
7. Cancer/Testis Antigens: Expression, Regulation, Tumor Invasion, and Use in Immunotherapy of Cancers.
Salmaninejad A; Zamani MR; Pourvahedi M; Golchehre Z; Hosseini Bereshneh A; Rezaei N
Immunol Invest; 2016 Oct; 45(7):619-40. PubMed ID: 27603913
[TBL] [Abstract][Full Text] [Related]
8. Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results.
Cluff CW
Adv Exp Med Biol; 2010; 667():111-23. PubMed ID: 20665204
[TBL] [Abstract][Full Text] [Related]
9. Clinical trials of dendritic cell-based cancer vaccines in hematologic malignancies.
Pyzer AR; Avigan DE; Rosenblatt J
Hum Vaccin Immunother; 2014; 10(11):3125-31. PubMed ID: 25625926
[TBL] [Abstract][Full Text] [Related]
10. Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides.
Kavanagh B; Ko A; Venook A; Margolin K; Zeh H; Lotze M; Schillinger B; Liu W; Lu Y; Mitsky P; Schilling M; Bercovici N; Loudovaris M; Guillermo R; Lee SM; Bender J; Mills B; Fong L
J Immunother; 2007 Oct; 30(7):762-72. PubMed ID: 17893568
[TBL] [Abstract][Full Text] [Related]
11. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy.
Bodey B; Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 2000; 20(4):2665-76. PubMed ID: 10953341
[TBL] [Abstract][Full Text] [Related]
12. Exosome targeting of tumor antigens expressed by cancer vaccines can improve antigen immunogenicity and therapeutic efficacy.
Rountree RB; Mandl SJ; Nachtwey JM; Dalpozzo K; Do L; Lombardo JR; Schoonmaker PL; Brinkmann K; Dirmeier U; Laus R; Delcayre A
Cancer Res; 2011 Aug; 71(15):5235-44. PubMed ID: 21670078
[TBL] [Abstract][Full Text] [Related]
13. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
[TBL] [Abstract][Full Text] [Related]
14. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
15. Genetically modified tumour vaccines--where we are today.
Nawrocki S; Mackiewicz A
Cancer Treat Rev; 1999 Feb; 25(1):29-46. PubMed ID: 10212588
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic vaccination with tumor cells that engage CD137.
Hellstrom KE; Hellstrom I
J Mol Med (Berl); 2003 Feb; 81(2):71-86. PubMed ID: 12601523
[TBL] [Abstract][Full Text] [Related]
17. SV-BR-1-GM, a Clinically Effective GM-CSF-Secreting Breast Cancer Cell Line, Expresses an Immune Signature and Directly Activates CD4
Lacher MD; Bauer G; Fury B; Graeve S; Fledderman EL; Petrie TD; Coleal-Bergum DP; Hackett T; Perotti NH; Kong YY; Kwok WW; Wagner JP; Wiseman CL; Williams WV
Front Immunol; 2018; 9():776. PubMed ID: 29867922
[TBL] [Abstract][Full Text] [Related]
18. Tecemotide: an antigen-specific cancer immunotherapy.
Wurz GT; Kao CJ; Wolf M; DeGregorio MW
Hum Vaccin Immunother; 2014; 10(11):3383-93. PubMed ID: 25483673
[TBL] [Abstract][Full Text] [Related]
19. Particulate formulations for the delivery of poly(I:C) as vaccine adjuvant.
Hafner AM; Corthésy B; Merkle HP
Adv Drug Deliv Rev; 2013 Oct; 65(10):1386-99. PubMed ID: 23751781
[TBL] [Abstract][Full Text] [Related]
20. The present status and future prospects of peptide-based cancer vaccines.
Hirayama M; Nishimura Y
Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]